AU2263197A - Diabetes therapy - Google Patents

Diabetes therapy

Info

Publication number
AU2263197A
AU2263197A AU22631/97A AU2263197A AU2263197A AU 2263197 A AU2263197 A AU 2263197A AU 22631/97 A AU22631/97 A AU 22631/97A AU 2263197 A AU2263197 A AU 2263197A AU 2263197 A AU2263197 A AU 2263197A
Authority
AU
Australia
Prior art keywords
diabetes therapy
diabetes
therapy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU22631/97A
Inventor
Tracy L. Borts
Carol L. Broderick
Richard D. Dimarchi
Brian W Grinnell
Anne R. Miller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9603847.6A external-priority patent/GB9603847D0/en
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2263197A publication Critical patent/AU2263197A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU22631/97A 1996-02-06 1997-02-06 Diabetes therapy Abandoned AU2263197A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US012111 1993-02-01
US1211196P 1996-02-06 1996-02-06
GB9603847 1996-02-23
GBGB9603847.6A GB9603847D0 (en) 1996-02-23 1996-02-23 Diabetes therapy
PCT/US1997/001978 WO1997029180A1 (en) 1996-02-06 1997-02-06 Diabetes therapy

Publications (1)

Publication Number Publication Date
AU2263197A true AU2263197A (en) 1997-08-28

Family

ID=26308793

Family Applications (1)

Application Number Title Priority Date Filing Date
AU22631/97A Abandoned AU2263197A (en) 1996-02-06 1997-02-06 Diabetes therapy

Country Status (5)

Country Link
EP (1) EP0879279A4 (en)
JP (1) JP2001503963A (en)
AU (1) AU2263197A (en)
CA (1) CA2243718A1 (en)
WO (1) WO1997029180A1 (en)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6117641A (en) 1996-04-11 2000-09-12 Mitotix, Inc. Assays and reagents for identifying anti-fungal agents and uses related thereto
US6727082B1 (en) 1996-04-11 2004-04-27 Gpc Biotech Inc. Assays and reagents for identifying anti-fungal agents, and uses related thereto
AU717165B2 (en) 1996-04-11 2000-03-16 Gpc Biotech Inc. Assays and reagents for identifying anti-fungal agents, and uses related thereto
JP2002510193A (en) * 1997-03-31 2002-04-02 イーライ・リリー・アンド・カンパニー Glucagon-like peptide-1 analog
WO1998043658A1 (en) * 1997-03-31 1998-10-08 Eli Lilly And Company Glucagon-like peptide-1 analogs
WO1999053064A2 (en) * 1998-04-13 1999-10-21 Modex Therapeutiques, S.A. Methods of delivering glp-1
CZ303120B6 (en) * 1998-12-07 2012-04-11 Societe De Conseils De Recherches Et Dapplications Scientifiques S. A. Compound and pharmaceutical composition
BR9915961A (en) 1998-12-07 2001-08-21 Sod Conseils Rech Applic Glp-1 analogs
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
AU783594B2 (en) * 1999-04-15 2005-11-10 South Eastern Sydney Area Health Service Method of prophylaxis and treatment of diabetes
AU1269501A (en) * 1999-11-12 2001-05-30 Novo Nordisk A/S Use of glp-1 agonists for the inhibition of beta cell degeneration
US6569832B1 (en) 1999-11-12 2003-05-27 Novo Nordisk A/S Inhibition of beta cell degeneration
IL149679A0 (en) 1999-11-19 2002-11-10 Transkaryotic Therapies Inc Nucleic acid construct and methods utilizing the same
US20020025306A1 (en) * 2000-01-07 2002-02-28 Baetge Edward E. Methods of increasing the glucose responsiveness of pancreatic ss-cells
CN1363654A (en) * 2001-07-19 2002-08-14 上海华谊生物技术有限公司 Genetically engineered bacteria and process for preparing insulinotropic hormone secretion peptide GLP-1 (7-36)
EP1694278A4 (en) 2003-12-16 2009-08-12 Ipsen Pharma Glp-1 pharmaceutical compositions
EP1711523B1 (en) 2003-12-16 2012-10-10 Ipsen Pharma Analogues of glp-1
TW200643033A (en) * 2005-03-08 2006-12-16 Chugai Pharmaceutical Co Ltd Conjugate of water-soluble modified hyaluronic acid and glp-1 analogue
WO2007056362A2 (en) 2005-11-07 2007-05-18 Indiana University Research And Technology Corporation Glucagon analogs exhibiting physiological solubility and stability
EP2124974B1 (en) 2007-01-05 2017-03-15 Indiana University Research and Technology Corporation Glucagon analogs exhibiting enhanced solubility in physiological ph buffers
EP2111414B1 (en) 2007-02-15 2014-07-02 Indiana University Research and Technology Corporation Glucagon/glp-1 receptor co-agonists
WO2009058734A1 (en) 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
ES2509883T3 (en) 2007-10-30 2014-10-20 Indiana University Research And Technology Corporation Glucagon antagonists
EA023069B1 (en) * 2008-04-09 2016-04-29 Корнелл Юниверсити Isolated recombinant enteric commensal bacteria and use thereof
US9062124B2 (en) 2008-06-17 2015-06-23 Indiana University Research And Technology Corporation GIP-based mixed agonists for treatment of metabolic disorders and obesity
EA019203B9 (en) 2008-06-17 2014-03-31 Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн Glucagon/glp-1 receptor co-agonists
KR20110039230A (en) 2008-06-17 2011-04-15 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Glucagon analogs exhibiting enhanced solubility and stability in physiological ph buffers
TWI489992B (en) 2008-12-19 2015-07-01 印地安那大學研究及技術公司 Amide based glucagon superfamily peptide prodrugs
MX2011013625A (en) 2009-06-16 2012-01-20 Univ Indiana Res & Tech Corp Gip receptor-active glucagon compounds.
EP2512503A4 (en) 2009-12-18 2013-08-21 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists
MX2012008603A (en) 2010-01-27 2013-01-25 Univ Indiana Res & Tech Corp Glucagon antagonist - gip agonist conjugates and compositions for the treatment of metabolic disorders and obesity.
EP2568993A4 (en) 2010-05-13 2014-02-19 Univ Indiana Res & Tech Corp Glucagon superfamily peptides exhibiting g protein-coupled receptor activity
ES2661228T3 (en) 2010-05-13 2018-03-28 Indiana University Research And Technology Corporation Glucagon superfamily peptides that show nuclear hormone receptor activity
WO2011163012A2 (en) 2010-06-24 2011-12-29 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
JP6033780B2 (en) 2010-10-15 2016-11-30 コーネル・ユニバーシティーＣｏｒｎｅｌｌ Ｕｎｉｖｅｒｓｉｔｙ Compositions and methods for treating endocrine disorders, gastrointestinal disorders or autoimmune disorders
PE20140186A1 (en) 2010-12-22 2014-02-13 Univ Indiana Res & Tech Corp GLUCAGON ANALOGS PRESENTING GIP RECEPTOR ACTIVITY
GEP20176629B (en) 2011-06-22 2017-02-27 Indiana Unversity Research And Tech Corporation Glucagon/glp-1 receptor co-agonists
MX2013015168A (en) 2011-06-22 2014-03-31 Univ Indiana Res & Tech Corp Glucagon/glp-1 receptor co-agonists.
KR20140097151A (en) 2011-11-17 2014-08-06 인디애나 유니버시티 리서치 앤드 테크놀로지 코퍼레이션 Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
JP6311708B2 (en) 2012-06-21 2018-04-18 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ Glucagon analog showing GIP receptor activity
CA3056663C (en) 2019-04-05 2022-10-18 Jeffrey S. RIESMEYER Use of dulaglutide in reducing risk of cardiovascular events in patients with type 2 diabetes mellitus

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5399346A (en) * 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
EP0499990B1 (en) * 1991-02-19 1996-05-15 Takeda Chemical Industries, Ltd. Method for producing cysteine-free peptides
NZ245015A (en) * 1991-11-05 1995-12-21 Transkaryotic Therapies Inc Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
NZ250844A (en) * 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US5512459A (en) * 1993-07-20 1996-04-30 Bionebraska, Inc. Enzymatic method for modification or recombinant polypeptides
GB9502830D0 (en) * 1995-02-14 1995-04-05 Ecole Polytech Regulation of polypeptide production in cells

Also Published As

Publication number Publication date
EP0879279A1 (en) 1998-11-25
WO1997029180A1 (en) 1997-08-14
CA2243718A1 (en) 1997-08-14
EP0879279A4 (en) 2000-07-12
JP2001503963A (en) 2001-03-27

Similar Documents

Publication Publication Date Title
AU2263197A (en) Diabetes therapy
AUPO203996A0 (en) Therapeutic uses
AU3550197A (en) Syringes
EP0796628A3 (en) Inhaler
AU2805195A (en) Therapeutic compounds
AU1673297A (en) Therapeutic agent for diabetes
AU1626297A (en) Syringe assembly
AU1184399A (en) Therapeutic molecules
AUPO434196A0 (en) An improved therapeutic
AU5721598A (en) Novel human thioredoxin
AU2547895A (en) Therapeutic phenoxyalkylheterocycles
AU6314496A (en) Insulin
AU5490298A (en) Syringe
AU1645599A (en) Human matrilin-3
AU5330198A (en) Therapeutic compounds
AU1714195A (en) Therapeutic benzonitriles
GB2304046B (en) Diabetes therapy
GB9603847D0 (en) Diabetes therapy
AU3978697A (en) Plasmin-depletion therapy
AU4124497A (en) Treatment of diabetes
AU2003200183A1 (en) Cholestrol-lowering Therapy
AUPO181796A0 (en) Therapeutic uses
AUPO878097A0 (en) Treatment for diabetes
AUPO651397A0 (en) Therapeutic thermal-pack
AUPO537497A0 (en) Therapeutic molecules - II